Transcriptional and Promoter–Driven Control of Adenovirus–Mediated
Yoko Yoshida and Hirofumi Hamada
Transcriptionally targeted adenoviral vectors which are able to restrict and regulate the levels of expression of the therapeutic gene will have wide applicability for gene therapy. For cancer gene therapy, tumor-specific promoters could be used to drive drug sensitivity genes (e.g., HSV-tk, cytosine deaminase) for suicide gene therapy, or E1A gene for restricted replication-competent adenovirus-mediated gene therapy. Candidate promoters are α-fetoprotein (AFP) promoter/enhancer, carcinoembryonic antigen (CEA) promoter, prostate-specific antigen (PSA) promoter, and so on (for review, see ref. 1). In addition to the tissue-specific promoter systems, inducible gene expression systems (for review, see ref.\r\n2) are also applicable for the control of adenovirus-mediated gene expression. In this chapter, first we make a brief review of the applications of adenoviruses with the tissue-specific promoters, with an emphasis on cancer gene therapy. Then we demonstrate our successful application of the tetracycline-inducible system for adenoviral vectors.